Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) generates news at the intersection of cell therapy, oncology and metabolic disease research. Company announcements and SEC-referenced disclosures describe a business that has combined T-cell receptor (TCR) cell therapy programs for solid tumors with a preclinical-stage obesity and metabolic health drug development effort built around a small molecule candidate.
News items for TCRT commonly cover clinical and translational updates from its TCR-T Library Phase 1/2 trial at The University of Texas MD Anderson Cancer Center, including disease control rates, objective responses in metastatic, refractory solid tumors, and safety and tolerability findings for its Sleeping Beauty-engineered TCR-T cells. Releases also highlight the capabilities of the hunTR ae TCR discovery platform, which the company reports has identified proprietary TCRs targeting driver mutations such as KRAS and TP53.
Investors following TCRT news will also see coverage of Alaunos strategic reprioritization and corporate actions. The company has publicly discussed winding down its TCR-T clinical trial, refocusing on the hunTR ae platform, and exploring strategic alternatives that may include acquisitions, mergers, reverse mergers, asset sales, partnerships or capital raises. Financial results releases detail research and development spending, restructuring costs, workforce reductions and cash runway expectations as the company adjusts its operations.
In addition, Alaunos issues news on capital markets activity, such as registered direct offerings of common stock and pre-funded warrants under a shelf registration statement, private offerings of convertible preferred stock, and equity purchase agreements registered on Form S-1. Governance and listing-related updates, including board changes, executive transitions and Nasdaq compliance notices and resolutions, also appear in the news flow. For readers tracking TCRT, this page aggregates these operational, clinical, financial and regulatory developments in one place.
Alaunos Therapeutics (Nasdaq: TCRT) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 5:00-5:30 PM ET at the Fontainebleau Miami Beach Hotel. The presentation will be delivered by CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. A live webcast will be available on the company's website, with replays accessible for 90 days. Alaunos focuses on T-cell receptor therapies for oncology, utilizing its proprietary Sleeping Beauty gene transfer technology and collaborating with leading cancer research institutions.
Alaunos Therapeutics (TCRT) is set to announce its financial results for the first quarter ending March 31, 2022, on May 16, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can join via phone or live webcast, with the event archived for 30 days post-call. Alaunos focuses on developing T-cell receptor therapies using proprietary gene transfer technology, with collaborations with MD Anderson Cancer Center and the National Cancer Institute.
Alaunos Therapeutics has announced a poster presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy, showcasing new preclinical data on its mbIL-15 program. This innovative cell therapy targets hotspot mutations in solid tumors, demonstrating enhanced survival capabilities. The research highlights the effectiveness of Sleeping Beauty transposed mbIL-15 TCR-T cells in improving clinical responses. The company plans to file an IND application for this program in H2 2023. The poster presentation is scheduled for May 16, 2022.
Alaunos Therapeutics has successfully dosed the first patient in its Phase 1/2 TCR-T Library trial targeting KRAS, TP53, and EGFR mutations in solid tumors. This milestone represents the first use of the company’s non-viral TCR-T cell therapy, manufactured in-house at its cGMP facility. The open-label study, conducted at MD Anderson Cancer Center, aims to determine the maximum tolerated dose and safety profile across various solid tumor types. Initial data is expected to be reported in the second half of 2022.
Alaunos Therapeutics, Inc. (TCRT) announced its fourth quarter and full year financial results for 2021, reporting a net loss of $11.8 million for Q4 and $78.8 million for the full year. Research and development expenses decreased to $8.2 million in Q4 from $14.0 million year-over-year. Significant milestones include the first patient consented in the Phase 1/2 TCR-T Library trial targeting solid tumors and an extended CRADA with the National Cancer Institute. As of December 31, 2021, the company had cash reserves of approximately $76.1 million.
Alaunos Therapeutics, Inc. (TCRT) will announce its fourth-quarter financial results for 2021 on March 30, 2022, before U.S. market open. Following this, a conference call and webcast will be held at 8:30 a.m. ET for a corporate update and financial review. Investors can access the call by dialing in or through a live webcast on the company’s website. Alaunos specializes in oncology-focused cell therapies, leveraging its Sleeping Beauty gene transfer platform, and has collaborations with notable institutions like MD Anderson Cancer Center and the National Cancer Institute.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced that CEO Kevin S. Boyle Sr. and VP of Research & Development Drew Deniger will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20am ET. The presentation will be available via a live webcast on the company’s website, with an archived replay accessible for 30 days. Alaunos focuses on oncology cell therapies, developing T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer technology and targeting major tumor-related mutations.